pi063 Antibody

What is the difference between PI3 Kinase p110 alpha and p110 delta antibodies in research applications?

PI3 Kinase p110 alpha (PIK3CA) and p110 delta antibodies target different isoforms of the PI3K catalytic subunit, each with distinct research applications. The p110 alpha antibody (such as 20583-1-AP) shows reactivity with human, mouse, and rat samples and is validated for Western Blot (WB), Immunohistochemistry (IHC), and ELISA applications . It particularly detects signals in multiple cell lines including HepG2, COLO 320, HeLa, and A431 cells, making it versatile for cancer research .

In contrast, PI3 Kinase p110 delta antibodies (like PIK3CD/4639) are primarily validated for human samples and are often conjugated with fluorescent labels such as Janelia Fluor 646 for enhanced detection sensitivity in immunofluorescence applications . The delta isoform plays crucial roles in autophagy and mTOR signaling pathways, making its antibodies particularly valuable for immune system and leukemia research .

What are the optimal dilution ranges for PI3K antibodies in Western Blotting?

The optimal dilution ranges for PI3K antibodies vary by specific antibody and application. For PI3 Kinase p110 alpha antibody (20583-1-AP), the recommended dilution for Western Blotting is 1:300-1:1000 . This relatively broad range acknowledges that optimal concentration depends on sample type and protein expression levels.

A methodological approach to determining the optimal dilution includes:

• Start with the manufacturer's recommended range (e.g., 1:500 for PIK3CA antibodies)

• Perform a dilution series experiment (1:300, 1:500, 1:750, 1:1000)

• Evaluate signal-to-noise ratio across dilutions

• Select the dilution that provides clear specific bands with minimal background

• Titrate the antibody in each specific testing system to optimize results

For p63 antibodies, similar principles apply, though specific dilution recommendations may differ based on the antibody clone and manufacturer specifications .

What storage conditions maximize antibody stability and shelf-life for PI3K and p63 antibodies?

Proper storage is crucial for maintaining antibody functionality. For PI3 Kinase p110 alpha antibodies, the recommended storage condition is -20°C, where they remain stable for one year after shipment . The storage buffer typically consists of PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . Importantly, aliquoting is unnecessary for -20°C storage of these antibodies, which simplifies laboratory handling protocols .

For fluorophore-conjugated antibodies like PI3 Kinase p110 delta with Janelia Fluor 646, storage at 4°C in the dark is recommended to prevent photobleaching and maintain fluorescent signal integrity .

For p63 antibodies, similar storage principles apply, with particular attention to avoiding repeated freeze-thaw cycles which can degrade antibody performance .

A methodological approach to antibody storage includes:

• Store at manufacturer-recommended temperature (-20°C for most PIK3CA antibodies)

• Protect fluorophore-conjugated antibodies from light exposure

• Maintain antibodies in their provided buffer systems

• Follow specific recommendations for antibodies containing preservatives like BSA (e.g., PIK3CA 20ul sizes contain 0.1% BSA)

How does antibody selection impact detection of PIK3CA mutations in cancer research?

PIK3CA mutations are associated with multiple cancer types including colorectal, breast, ovarian, and hepatocellular carcinoma . Selecting appropriate antibodies for mutation detection requires consideration of:

• Epitope location: Antibodies targeting regions affected by common mutations may show altered binding

• Mutation-specific antibodies: Some antibodies are designed to specifically detect mutant forms

• Wild-type vs. mutant detection: Consider whether research requires distinguishing between wild-type and mutant proteins

For effective research on PIK3CA mutations, a methodological approach includes:

• Using antibodies with epitopes in conserved regions for total protein detection

• Validating antibody performance in cell lines with known PIK3CA mutation status

• Complementing antibody-based detection with genetic testing methods

• Considering phospho-specific antibodies to examine downstream signaling effects of mutations

What are the recommended protocols for antigen retrieval when using PI3K antibodies in immunohistochemistry?

Effective antigen retrieval is critical for successful immunohistochemistry with PI3K antibodies. For PI3 Kinase p110 alpha antibody (20583-1-AP), the suggested antigen retrieval protocol uses TE buffer at pH 9.0 . Alternatively, citrate buffer at pH 6.0 may be used, though this is noted as a secondary option .

A detailed methodological approach includes:

• Buffer selection: Primary recommendation is TE buffer (pH 9.0)

• Alternative protocol: Citrate buffer (pH 6.0) if TE buffer yields suboptimal results

• Tissue-specific considerations: Human cervical cancer tissue has been validated with these retrieval methods

• Dilution range: Use 1:50-1:500 dilution for IHC applications

• Validation: Perform positive controls with known positive tissues

For PI 3-Kinase p110 delta antibodies in paraffin-embedded tissues, similar principles apply, though specific buffer recommendations may vary by antibody and target tissue .

How can researchers troubleshoot non-specific binding in Western blots using PI3K antibodies?

Non-specific binding is a common challenge when using PI3K antibodies in Western blotting. A systematic troubleshooting approach includes:

• Verify molecular weight: PI3 Kinase p110 alpha has a calculated molecular weight of 124 kDa but is typically observed at 120-130 kDa on Western blots

• Optimize blocking: Use appropriate blocking buffers (e.g., overnight blocking with Pierce blocking buffer at 4°C)

• Titrate antibody concentration: Test dilutions within the recommended range (1:300-1:1000 for PIK3CA)

• Adjust washing conditions: Implement stringent washing with PBS-T (PBS + 0.1% Tween-20) with 5 washes of 5 minutes each

• Validate with positive controls: Use known positive cell lysates such as HepG2, COLO 320, HeLa, or A431 cells for PIK3CA

If non-specific bands persist, consider using more specific detection methods or validating with knockout/knockdown controls to confirm antibody specificity.

How can researchers utilize PI3K antibodies to study the relationship between PI3K signaling and tumor growth?

PI3K signaling plays a crucial role in tumor growth, and antibodies targeting PI3K can be valuable tools for investigating these mechanisms. Research has shown that sub-lytic levels of antibodies may paradoxically accelerate tumor growth through PI3K-mediated mechanisms .

A methodological approach to studying PI3K signaling in cancer includes:

• Combined antibody and inhibitor studies: Test PI3K antibodies alongside PI3K inhibitors like NVP-BEZ235 at varying concentrations (0.005, 0.5, or 5 μg/ml) to assess pathway dependency

• Cell viability assays: Utilize WST-1 assays to quantify cellular responses to antibody treatment with and without PI3K inhibition

• Signaling cascade analysis: Use phospho-specific antibodies to monitor downstream effectors of PI3K

• In vivo models: Design survival studies to assess the impact of antibody-mediated PI3K modulation on tumor growth

• Statistical analysis: Apply Kaplan-Meier methodology and logrank testing to evaluate treatment effects on survival outcomes

This approach allows researchers to delineate complex roles of PI3K in tumor biology, particularly how antibody-mediated effects may depend on concentration, complement activation, and concurrent pathway modulation.

What are the considerations for using p63 antibodies in studying epithelial morphogenesis and stem cell biology?

The p63 protein plays critical roles in epithelial morphogenesis and stem cell maintenance. According to research data, p63 functions as a sequence-specific DNA binding transcriptional activator or repressor, with isoform-specific activities .

When designing experiments using p63 antibodies to study epithelial development:

• Isoform specificity: Consider whether the antibody detects all p63 isoforms or is specific for particular variants (TA* vs. DeltaN-type isoforms)

• Functional domains: Select antibodies that target relevant functional domains based on research questions about transactivation or repression activities

• Co-factor interactions: Design experiments to examine p63 interactions with co-factors like TP73/p73 in apoptosis regulation

• Developmental timing: When studying embryonic development, consider the timing of p63 expression in relation to epithelial stratification

• Signaling crosstalk: Include markers for related pathways, particularly Notch signaling components like JAG1 and JAG2

A comprehensive approach would examine both the ratio of different p63 isoforms and their specific functions in maintaining epithelial stem cell compartments, which is crucial for understanding epithelial development and homeostasis .

What methodological approaches can improve detection sensitivity when working with low-abundance PI3K isoforms?

Detecting low-abundance PI3K isoforms presents significant technical challenges. Advanced methodological approaches to improve detection sensitivity include:

• Signal amplification systems: Consider using tyramide signal amplification for IHC or enhanced chemiluminescence systems for Western blotting

• Enrichment strategies: Implement immunoprecipitation prior to Western blotting to concentrate the target protein

• Fluorophore selection: Choose high-quantum yield fluorophores like Janelia Fluor 646 for immunofluorescence applications

• Sample preparation optimization: For tissue samples, optimized antigen retrieval methods significantly impact detection sensitivity

• Positive control selection: Use cell lines known to express higher levels of the specific PI3K isoform as positive controls

How can multiplexed antibody approaches be used to study PI3K pathway activation in complex tissue samples?

Studying PI3K pathway activation in heterogeneous tissues requires sophisticated multiplexed antibody approaches:

• Multi-color immunofluorescence: Combine PI3K antibodies with antibodies against downstream effectors (e.g., phospho-AKT, phospho-S6K) using spectrally distinct fluorophores

• Sequential immunohistochemistry: Implement cyclic immunofluorescence or multiplexed IHC to detect multiple markers on the same tissue section

• Cell type-specific analysis: Include lineage markers to distinguish PI3K activation patterns in different cell populations within the tissue

• Spatial analysis: Employ digital pathology tools to quantify spatial relationships between PI3K-expressing cells and other features of the tissue microenvironment

• Validation strategies: Use appropriate positive and negative controls, including tissues from PI3K inhibitor-treated samples

This approach enables researchers to unravel the complex interplay between PI3K signaling and various cell types within the tissue context, providing insights into how pathway activation contributes to both normal physiology and disease states.

How should researchers interpret discrepancies between antibody-based detection of PI3K expression and functional PI3K activity?

Reconciling antibody-detected protein expression with functional enzyme activity requires careful experimental design and data interpretation:

• Complementary approaches: Combine antibody detection of PI3K protein levels with functional kinase assays measuring phosphorylation of PtdIns, PtdIns4P, and PtdIns(4,5)P2

• Post-translational modifications: Consider that PI3K activity may be regulated by PTMs not detected by antibodies against total protein

• Subcellular localization: Assess whether the antibody detection method preserves information about protein localization, which may affect activity

• Interacting proteins: Evaluate the presence of regulatory subunits or inhibitory proteins that modulate kinase activity

• Methodological limitations: Acknowledge that antibody epitope accessibility may be affected by protein conformation or complex formation

When discrepancies arise, a systematic approach includes validating findings with multiple antibody clones, correlating protein detection with mRNA expression data, and performing functional studies with specific PI3K inhibitors to confirm pathway dependencies.

What are the best experimental controls when using PI3K and p63 antibodies in cancer research studies?

Rigorous control strategies are essential for reliable antibody-based research, particularly in cancer studies:

For cancer studies specifically:

• Include both tumor and matched normal tissues

• Consider using cell lines with known PIK3CA mutations or p63 expression profiles

• Implement pharmacological controls using PI3K inhibitors like NVP-BEZ235

• For survival studies, include appropriate vehicle controls and use statistical approaches like Kaplan-Meier analysis

What methodological considerations are important when using PI3K antibodies to study autophagy and mTOR signaling?

PI3K plays a critical role in autophagy and mTOR signaling pathways . When designing experiments to investigate these processes:

• Isoform selection: Different PI3K isoforms have distinct roles in autophagy; PI3K class III (Vps34) is particularly important for autophagosome formation, while class I PI3Ks (including p110 alpha and delta) typically inhibit autophagy through mTOR activation

• Temporal dynamics: Include multiple time points to capture the dynamic nature of autophagy flux

• Complementary markers: Combine PI3K antibodies with antibodies against autophagy markers (LC3, p62) and mTOR pathway components (phospho-mTOR, phospho-S6K)

• Nutrient conditions: Assess PI3K localization and activity under both nutrient-rich and starvation conditions

• Pharmacological manipulation: Include controls with specific inhibitors of PI3K (class I vs. class III) and mTOR

A comprehensive experimental approach would examine:

• PI3K localization relative to autophagosome formation sites

• Changes in PI3K activity during autophagy induction and completion

• Correlation between PI3K activity and mTOR pathway status

• Effects of modulating PI3K activity on autophagic flux and mTOR signaling

This integrated approach allows researchers to delineate the complex relationships between PI3K signaling, autophagy regulation, and mTOR pathway activity in both normal physiology and disease states.

What emerging technologies are enhancing antibody-based detection of PI3K pathway components?

The field of antibody-based detection continues to evolve with technological innovations that enhance specificity, sensitivity, and multiplexing capabilities. For PI3K pathway research, emerging approaches include:

• Next-generation fluorophores: Novel fluorescent tags like Janelia Fluor 646 offer improved brightness and photostability for detecting low-abundance PI3K isoforms

• Proximity ligation assays: These methods allow visualization of protein-protein interactions between PI3K and binding partners or substrates

• Single-cell antibody-based proteomics: Techniques like CyTOF (mass cytometry) enable detection of multiple PI3K pathway components at the single-cell level

• Spatial transcriptomics integration: Combining antibody-based protein detection with spatial transcriptomics provides insights into regional heterogeneity of PI3K pathway activation

• AI-assisted image analysis: Machine learning algorithms improve quantification of antibody staining patterns in complex tissues